Can I continue denosumab (Prolia) after a routine dental filling repair?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can You Continue Prolia After a Routine Dental Filling Repair?

Yes, you can safely continue denosumab (Prolia) after a routine dental filling repair without interruption, as fillings are non-invasive procedures that do not involve manipulation of bone or extraction of teeth. 1

Understanding the Risk: What Dental Procedures Matter

The concern with denosumab relates specifically to osteonecrosis of the jaw (ONJ), which occurs when bone in the jaw becomes exposed and fails to heal. However, this complication is primarily associated with invasive dental procedures, not routine restorative work 2, 3.

Invasive vs. Non-Invasive Procedures

Invasive procedures that require caution include: 1, 3

  • Tooth extractions
  • Dental implant placement
  • Oral surgery
  • Periodontal surgery involving bone
  • Any procedure that traumatizes or exposes jawbone

Non-invasive procedures that are safe include: 1

  • Routine dental fillings (restorations)
  • Dental cleanings (non-surgical periodontal therapy when no bone involvement)
  • Root canals without apical surgery
  • Crown preparations

The Evidence on Dental Fillings and Denosumab

A routine filling repair involves only the tooth structure itself—removing decay and placing restorative material—without any manipulation of the underlying bone. The FDA label for Prolia specifically identifies risk factors for ONJ as "invasive dental procedures (e.g., tooth extraction, dental implants, oral surgery)" but does not list routine restorative procedures like fillings 1.

The key distinction is bone involvement: ONJ develops when bone is exposed or traumatized during dental work, which does not occur with standard filling procedures 2, 3.

What You Should Do

Continue your Prolia injections on schedule. 1 There is no need to delay or discontinue denosumab for routine dental fillings 3.

Maintain Preventive Measures

Even though fillings are safe, you should maintain these ongoing precautions while on Prolia: 1, 3

  • Practice excellent oral hygiene (brushing, flossing, fluoride mouthwash)
  • Attend regular dental check-ups every 6 months
  • Address any dental problems promptly before they require invasive treatment
  • Ensure adequate calcium and vitamin D supplementation

Important Caveats for Future Dental Work

If you ever need an invasive dental procedure (extraction, implant, oral surgery): 3, 1

  • Discuss timing with both your dentist and prescribing physician
  • Some experts suggest temporarily suspending denosumab may help ONJ resolution if it occurs, though this must be balanced against increased fracture risk 3
  • Complete all necessary invasive dental work before starting denosumab if possible 2, 3
  • If invasive work is needed while on denosumab, ideally delay the next dose for 14-21 days after the procedure to allow initial bone healing, if clinically appropriate 2

The Rebound Risk

Never abruptly stop Prolia without transitioning to another osteoporosis medication. Discontinuing denosumab leads to rapid bone loss and significantly increased risk of multiple vertebral fractures starting as early as 7 months after the last dose 1, 4. If denosumab must be stopped for more than 6 months, transition to a bisphosphonate to prevent rebound bone loss 2, 1.

Bottom Line

A dental filling is a routine, non-invasive procedure that poses no increased risk for ONJ. Continue your Prolia treatment without interruption, maintain good oral hygiene, and keep your regular dental appointments to prevent problems that might require invasive treatment in the future 1, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Denosumab-Related Osteonecrosis of the Jaw

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Biologic Antiresorptive: Denosumab.

Indian journal of orthopaedics, 2023

Related Questions

How to manage osteonecrosis of the maxillary bone caused by denosumab (Prolia/Xgeva)?
What are the adult indications, dosing regimens, contraindications, monitoring requirements, and alternative therapies for denosumab?
In an older adult with osteoporosis (e.g., post‑menopausal woman), does Prolia (denosumab) cause medication‑related osteonecrosis of the jaw, and what alternative osteoporosis therapies are available that do not carry this risk?
Does Prolia (denosumab) increase the healing of fractured bone?
What is the better medication for treating lumbar osteoporosis, Prolia (denosumab) or Reclast (zoledronic acid)?
Is a regimen of Admelog (insulin lispro) 25 units three times daily plus Tuojeo (insulin glargine) 40 units, increased by 2 units every 3 days until fasting blood glucose is <10 mmol/L, appropriate for a 220‑lb patient with an A1C of 11.1%?
What are the benefits, risks, and dosing considerations of selective serotonin reuptake inhibitors versus duloxetine and bupropion (Wellbutrin) for a female patient, particularly in the geriatric population?
What is the recommended antihypertensive treatment strategy for patients with hypertension and comorbid conditions such as chronic kidney disease (eGFR < 60 mL/min/1.73 m²) or diabetes with albuminuria, heart failure with reduced ejection fraction, prior myocardial infarction or stable coronary artery disease, African or Caribbean ancestry, isolated systolic hypertension in adults over 65, asthma or chronic obstructive pulmonary disease, contraindications to ACE inhibitors/ARBs, and resistant hypertension?
What is the most appropriate initial management for a patient with acute intermittent abdominal pain and vomiting after meals?
What starting dose of atomoxetine (Strattera) is recommended for a 42‑year‑old man with ADHD, how should it be ordered, and what baseline vital signs and laboratory tests are needed before initiating therapy?
What is the most likely diagnosis and appropriate management for a 42‑year‑old woman with a left knee effusion that yielded 22 mL clear straw‑colored fluid, nucleated cell count 450 cells/µL (normal ≤200), few red blood cells, no crystals, and a degenerated cell population on synovial analysis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.